These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 30275703)

  • 1. PD1/PDL1 inhibitors for the treatment of advanced urothelial bladder cancer.
    Stenehjem DD; Tran D; Nkrumah MA; Gupta S
    Onco Targets Ther; 2018; 11():5973-5989. PubMed ID: 30275703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Approved checkpoint inhibitors in bladder cancer: which drug should be used when?
    Ghatalia P; Zibelman M; Geynisman DM; Plimack E
    Ther Adv Med Oncol; 2018; 10():1758835918788310. PubMed ID: 30083254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging Role of Immunotherapy in Advanced Urothelial Carcinoma.
    Koshkin VS; Grivas P
    Curr Oncol Rep; 2018 Apr; 20(6):48. PubMed ID: 29644490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitors: the new treatment paradigm for urothelial bladder cancer.
    Katz H; Wassie E; Alsharedi M
    Med Oncol; 2017 Sep; 34(10):170. PubMed ID: 28864844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Urothelial carcinoma in the era of immune checkpoint inhibitors.
    Khalife N; Chahine C; Kordahi M; Felefly T; Kourie HR; Saleh K
    Immunotherapy; 2021 Aug; 13(11):953-964. PubMed ID: 34184561
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy in Urothelial Cancer: Recent Results and Future Perspectives.
    Farina MS; Lundgren KT; Bellmunt J
    Drugs; 2017 Jul; 77(10):1077-1089. PubMed ID: 28493171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationale and Outcomes for Neoadjuvant Immunotherapy in Urothelial Carcinoma of the Bladder.
    Rouanne M; Bajorin DF; Hannan R; Galsky MD; Williams SB; Necchi A; Sharma P; Powles T
    Eur Urol Oncol; 2020 Dec; 3(6):728-738. PubMed ID: 33177001
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nivolumab for the treatment of urothelial cancers.
    Teo MY; Rosenberg JE
    Expert Rev Anticancer Ther; 2018 Mar; 18(3):215-221. PubMed ID: 29363363
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunotherapy in Bladder Cancer.
    Konala VM; Adapa S; Aronow WS
    Am J Ther; 2022 May-Jun 01; 29(3):e334-e337. PubMed ID: 30839322
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immune Checkpoint Inhibitors for the Treatment of Bladder Cancer.
    Lopez-Beltran A; Cimadamore A; Blanca A; Massari F; Vau N; Scarpelli M; Cheng L; Montironi R
    Cancers (Basel); 2021 Jan; 13(1):. PubMed ID: 33401585
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Systemic Immunotherapy for Urothelial Cancer: Current Trends and Future Directions.
    Gupta S; Gill D; Poole A; Agarwal N
    Cancers (Basel); 2017 Jan; 9(2):. PubMed ID: 28134806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.
    Tripathi A; Plimack ER
    Curr Urol Rep; 2018 Nov; 19(12):109. PubMed ID: 30406502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Biomarkers for immunotherapy in bladder cancer: a moving target.
    Aggen DH; Drake CG
    J Immunother Cancer; 2017 Nov; 5(1):94. PubMed ID: 29157296
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advances and Controversies With Checkpoint Inhibitors in Bladder Cancer.
    Rhea LP; Aragon-Ching JB
    Clin Med Insights Oncol; 2021; 15():11795549211044963. PubMed ID: 34602833
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges.
    Giroux Leprieur E; Dumenil C; Julie C; Giraud V; Dumoulin J; Labrune S; Chinet T
    Eur J Cancer; 2017 Jun; 78():16-23. PubMed ID: 28407528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of immunotherapy in bladder cancer: present and future on targeting PD(L)1 and CTLA-4 pathways.
    Rouanne M; Roumiguié M; Houédé N; Masson-Lecomte A; Colin P; Pignot G; Larré S; Xylinas E; Rouprêt M; Neuzillet Y
    World J Urol; 2018 Nov; 36(11):1727-1740. PubMed ID: 29855698
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma.
    Patel A; Bisno DI; Patel HV; Ghodoussipour S; Saraiya B; Mayer T; Singer EA
    J Cancer Immunol (Wilmington); 2021; 3(2):115-136. PubMed ID: 34263255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy.
    Suzman DL; Agrawal S; Ning YM; Maher VE; Fernandes LL; Karuri S; Tang S; Sridhara R; Schroeder J; Goldberg KB; Ibrahim A; McKee AE; Pazdur R; Beaver JA
    Oncologist; 2019 Apr; 24(4):563-569. PubMed ID: 30541754
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Outcomes of Platinum-ineligible Patients with Advanced Urothelial Carcinoma Treated With First-line PD1/L1 Inhibitors.
    Pond GR; Agarwal A; Ornstein M; Garcia J; Gupta R; Grivas P; Drakaki A; Lee JL; Kanesvaran R; Lorenzo GD; Verolino P; Barata P; Bilen MA; Hussain SA; Curran C; Sonpavde G
    Clin Genitourin Cancer; 2021 Oct; 19(5):425-433. PubMed ID: 34006497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update of systemic immunotherapy for advanced urothelial carcinoma.
    Gartrell BA; He T; Sharma J; Sonpavde G
    Urol Oncol; 2017 Dec; 35(12):678-686. PubMed ID: 29079131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.